Navigation Links
Cardiome kündigt Anwesenheit auf dem ESC Congress 2013 in Amsterdam an
Date:8/30/2013

160;          (Die wirtschaftlichen Aspekte des Vorhofflimmerns)

    13:35 - 13:50: J. Hartikainen (Kuopio, FI); Real-life experience with vernakalant:

           Who is the right patient for this drug?

           (Erfahrungen aus dem echten Leben mit Vernakalant: Wie sieht der richtige Patient für diese Droge aus?)

    13:50 - 14:00: Abschluss und abschließende Bemerkungen

Eine Internetübertragung des Symposiums wird der Öffentlichkeit auf der Website des ESC Congress 365 (http://congress365.escardio.org/home.aspx) bis September 2014 zur Verfügung gestellt.

Informationen zu Cardiome Pharma Corp.
Cardiome Pharma Corp. ist ein Biopharmaunternehmen, welches sich der Entdeckung, Entwicklung und der Kommerzialisierung von neuen Therapien verschrieben hat, welche der Gesundheit von Patienten auf der ganzen Welt zugutekommt. Cardiome verfügt in Europa und anderen Gebieten über ein auf den Markt gebrachtes Produkt, BRINAVESS[TM] (Vernakalant IV) - für die schnelle Kardioversion von jüngst ausgebrochenen Vorhofflimmern zu einem Sinusrhythmus bei Erwachsenen.

Cardiome wird am NASDAQ Capital Market (CRME) und der Toronto Stock Exchange (COM) gehandelt. Weiterführende Informationen erhalten Sie auf unserer Website unter http://www.cardiome.com.

Haftungsausschluss zu zukunftsbezogenen Aussagen
Bestimmte Aussagen in dieser Pressemitteilung enthalten zukunftsbezogene Aussagen im Sinne des Private Securities Litigation Reform Act von 1995 oder zukunftsbezogene Aussagen im Sinne geltender kanadischer Wertpapiergesetze. Dabei handelt es sich um Aussagen, die nicht auf historischen Tatsachen beruhen und unter anderem Wörter wie "glau
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CardioMEMS Named as a Finalist for Intel Innovation Award
2. CardioMEMS, Inc. wins 2012 Intel Innovation Award
3. CardioMEMS Vice President - Information Systems, Richard Powers, and Chairman of the Board, John Huntz, Selected as Finalists for Prestigious Awards
4. CardioMEMS CFO, Daniel H. Bauer, Honored with a CFO of the Year Award by the Atlanta Business Chronicle
5. Cardiome anuncia su presencia en el Congreso ESC 2013 en Ámsterdam
6. GenScript kündigt gemeinsame Roadshow mit Open Monoclonal Technology, Inc. an
7. Simbionix kündigt Lizenzvertrag für chirurgische Videos an
8. Blue Belt Technologies kündigt Gründung eines wissenschaftlichen Beirats für Hüfteingriffe zur Bestimmung neuer Anwendungsgebiete von NavioPFS bei femoro-acetabulärem Impingement an
9. Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an
10. CryoLife kündigt erste Implantation des HeRO Transplantats in Europa an
11. STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... SUNNYVALE, Calif., May 1, 2015 Pharmacyclics, Inc. ... results for the quarter ended March 31, 2015, as ... merger with AbbVie Inc., no conference call will be held. ... the quarter ended March 31, 2015 increased to $206 ... 31, 2014. , Worldwide IMBRUVICA ® (ibrutinib) ...
(Date:5/1/2015)... May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... E. Morris , chief financial officer  will be participating ... are as follows: Mizuho Third Annual Healthcare ... Omni Berkshire Place, New York ...
(Date:4/30/2015)... 2015 Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the fourth quarter and ... quarter and fiscal 2015 overview: , Revenues from ... up 33% over last year,s comparable quarter, and $202.6 ... Diluted EPS of $0.50 for the fourth quarter, up ...
Breaking Medicine Technology:Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3
... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET ) ... by the United States Patent and Trademark Office (USPTO) relating ... to treat liver disease.  Under the terms of its license ... exclusive licensee of U.S. patent 7,935,528.   The ...
... Pa., May 31, 2011 West Pharmaceutical Services, Inc. (NYSE: ... the Jefferies 2011 Global Healthcare Conference in New York, NY. ... on Monday, June 6, 2011 at 4:00 PM ET. ... well as a copy of the presentation materials, will be ...
Cached Medicine Technology:MultiCell Technologies is Granted Stem Cell Patent 2MultiCell Technologies is Granted Stem Cell Patent 3
(Date:5/2/2015)... 02, 2015 As a nonsurgical ... of the face, neck and décolleté, radiofrequency energy ... real potential for the success of vulvovaginal rejuvenation. ... Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory ... concluded that ThermiGyn’s temperature controlled radio frequency, specifically ...
(Date:5/2/2015)... success that Veatch Dental Consulting has had over the years, ... Shields to the team. With Neida and Alex on board, ... working with dentists to ensure their success. , Neida Miranda ... She was certified as dental assistant from Texas State Technical ... the importance of oral hygiene to patients, Neida was moved ...
(Date:5/1/2015)... May 02, 2015 The Venetian on ... http://www.thevenetiangracebay.com , and it is elegant and sophisticated, ... white and attractive turquoise hues of Grace Bay Beach. ... seven percent of leisure travelers used their smartphones throughout ... were used in the planning and researching and continued ...
(Date:5/1/2015)... Anaheim, CA (PRWEB) May 01, 2015 ... Ethos Award for the successful repositioning of its flagship ... its company brand with a new name, new logo, ... The DSA Ethos Awards are designed to identify and ... at its best. , “DSA congratulates Jusuru International ...
(Date:5/1/2015)... RESTON, Va. (PRWEB) May 01, 2015 ... the nation’s leading nonprofit authority on the use of ... served as a key contributing resource to the United ... the use of electronically readable cards in Medicare. The ... Beneficiaries and Providers ” was released to the public ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
... Presentation to highlight milestones including phase III development of ... What: Horizon Therapeutics, Inc. is pleased to announce that ... M.D., Ph.D., chief executive officer, will ... including its recent completion of Series C financing, and ...
... Twelve of Sixteen FH Patients in an Ongoing Open-Label Extension Study,Have Been Dosed With ... Four Have Been Dosed for More Than ... 8:00 a.m. E.T. ... at http://www.isispharm.com , CARLSBAD, Calif., Oct. 5 Isis,Pharmaceuticals, Inc. (Nasdaq: ...
... knows about the,FDA,s impending ban on children,s cold ... scramble to find other ways to alleviate their ... recently,introduced into the U.S. -- offers a safe ... According to the FDA, popular medicines such ...
... SOUTH SAN FRANCISCO, Calif., Oct. 4 Sunesis,Pharmaceuticals, Inc. ... inducement stock options awards in accordance with NASDAQ,Marketplace Rule ... stock options cover an aggregate of 48,000 shares of,common ... an,exercise price equal to the fair market value of ...
... U.S. may,be breathing its last gasps, as the ... Passage in the House is expected to be ... past six years, this legislation would,finally ban asbestos, ... asbestos, most deadly cancer, mesothelioma (meso), and other,asbestos-related ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced the appointment ... Company,s new independent auditor effective October,2, 2007. BPM, ... the Audit Committee of the Company,s Board of ... with several,public accounting firms. BPM replaces PricewaterhouseCoopers LLP. ...
Cached Medicine News:Health News:Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting 2Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 2Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 3Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 4Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 5Health News:Nosefrida Nasal Aspirator - A Parent's Alternative to Medicines on the Verge of FDA Ban 2Health News:Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 3Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 4
... on delicate urethral tissues. The ... coating provide nearly friction-free movement, ... easy to maintain sterility. You ... its own sterile water, avoiding ...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... Rochester Medical's line of ... intermittent catheters you would ... four product configurations - ... antibacterial hydro - are ...
Active Cath is a latex, self-adhering, one piece catheter designed for extended wear. It combines a shortened latex sheath with a wide adhesive seal....
Medicine Products: